PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North America
May 24 2022 - 8:30AM
InvestorsHub NewsWire
PSYC Teams Up with The Spore Group to
Bring Industry-Leading, Psychedelic-Focused Events to Communities
Across North
America
LAS VEGAS, NV -- May 24, 2022 -- InvestorsHub
NewsWire -- PSYC
Corporation (OTCPink:
PSYC) (“PSYC” or the “Company”) a media leader for the emerging
sector of medicinal psychedelics and authorities behind
Psychedelic
Spotlight, a
top ranking psychedelic news and information platform, is pleased
to announce that PSYC’s wholly owned subsidiary, Spotlight Media
Group, entered into a Collaboration Partnership Agreement with
The
Spore Group (“TSG”), an organization focused on bridging the
gap between education, legislation, regulation, and investing in
psychedelics, with the intent of producing industry-leading
conferences and events for the emerging psychedelic
sector.
Combining the valuable leadership experience of the
TSG executive team with the substantial reach and presence
established by PSYC’s Psychedelic Spotlight throughout the
psychedelic’s community, the companies will kick off their
partnership with Sol
Pschedelphia, a celebration of the psychedelic revival, to be
held at the One Art Community Center in Philadelphia, PA on Friday,
June 24th, 2022.
Over the next several months, the companies plan to
collaborate on the production of a variety of additional
education-inspired events and conferences, both in live and virtual
format, in an effort to create informative and thought-provoking
conversations surrounding the exciting potential of
psychedelic-assisted healing at a grass roots, community-focused
level.
“As excited and optimistic as we are here at PSYC
over the long-term value potential of the psychedelic space, we
recognize the many challenges that are present in terms of exactly
how psychedelic-assisted healing will develop a fully legal and
effective pathway to accessibility and affordability within
communities frequently left behind by Big Pharma,” said PSYC CEO,
David Flores. “In recent months, I’ve had the pleasure of joining
several, productive conversations with TSG’s Co-Founder and COO,
Joe Barnes. We identified a shared passion for creating grassroots
movements that begin and end at the very heart of the communities
with which we hope to make a positive
impact.”
“Moreover,” Flores continued, “this partnership with
TSG creates an opportunity for our companies to combine resources
and work towards this shared goal in a far more effective manner
than independently. I’m also not overlooking the larger, long term
value potential this partnership can deliver to each company
through an array of additional collaboration opportunities worth
exploring together in the second half of
2022.”
As part of this partnership, Psychedelic Spotlight
will leverage its branding, marketing and content production
expertise to operate as the official promotional partner for any
TSG events on which the companies agree to collaborate and will
allow for the Company to earn a percentage of gross revenue derived
from any such events.
“Mr. Flores has extensive experience in the emerging
Psychedelic Industry,” said Joe Barnes, Chief Operating Officer of
The Spore Group. “He has built an amazing team which can assist in
our endeavor to create a grass-roots movement to educate the public
and expand the use of Traditional Plant
Medicines.”
In the coming
weeks, the companies plan to release additional information related
to Sol Pschedelphia through each of their respective platforms,
including Psychedelic Spotlight and its related social media
channels.
About PSYC
Corporation (OTCPink:
PSYC)
At PSYC
Corporation we are integrating media, creativity, and technology to
develop and deploy thought-provoking ideas and solutions that are
fostering and transforming the approach to some of society’s most
pressing matters.
PSYC has
expressed its intent and commitment to positioning itself at the
forefront of the psychedelic revolution and as a resource center
for discovering and understanding the latest research and business
opportunities surrounding psychedelic inspired medicines. In
conjunction with the FDA’s more open-minded approach to psychedelic
medicines, and as several major U.S. cities continue to approve the
decriminalization of psilocybin, we believe investors are
speculating that the psychedelic boom could be bigger than that of
cannabis. PSYC is your source for current investment related news
specific to psychedelic medicines and cutting-edge research
improving overall health, moving this sector into the
mainstream.
We are
dedicated to a forward-thinking approach that embraces
groundbreaking new technology and innovations and through the
vision of business development we intend to continue to evolve into
these unchartered territories as the industry leaders of the
future.
Forward-Looking Statements Disclaimer:
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. In some
cases, you can identify forward-looking statements by the following
words: "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "ongoing," "plan," "potential,"
"predict," "project," "should," "will," "would," or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements are not a guarantee of future performance or results and
will not necessarily be accurate indications of the times at, or
by, which such performance or results will be achieved.
Forward-looking statements are based on information available at
the time the statements are made and involve known and unknown
risks, uncertainty and other factors, including the effect of
COVID-19 and the success of the current vaccine distribution, the
adverse effect of the Omicron variant, that may cause our results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by the
forward-looking statements in this press release. This press
release should be considered in light of all filings of the Company
that are disclosed on the OTC Markets.com website and is not
incorporated by reference into such
reports.
Disclaimer: PSYC Corporation does not in any way encourage or
condone the use, purchase, sale or transfer of any illegal
substances, nor do we encourage or condone partaking in any
unlawful activities. We support a harm reduction approach for the
purpose of education and promoting individual and public safety. If
you are choosing to use psychedelic substances, please do so
responsibly.
Corporate
Contact:
PSYC
Corporation (PSYC)
www.psyccorporation.com
(702)
761-6716
info@psyccorporation.com
OTCPINK:
PSYC
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Sep 2023 to Sep 2024